Free Trial
NASDAQ:UPB

Upstream Bio Q1 2026 Earnings Report

Upstream Bio logo
$8.97 -0.14 (-1.55%)
As of 12:49 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Upstream Bio EPS Results

Actual EPS
N/A
Consensus EPS
-$0.80
Beat/Miss
N/A
One Year Ago EPS
N/A

Upstream Bio Revenue Results

Actual Revenue
N/A
Expected Revenue
$0.42 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Upstream Bio Announcement Details

Quarter
Q1 2026
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Upstream Bio Earnings Headlines

Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of the world's oil passing through that corridor, crude has already crossed $100 per barrel. History shows gold surged 571% during the 1973 oil crisis and 425% in 1979. Today, the U.S. holds 8,133 tonnes of gold valued on the books at $42.22 per ounce - while gold trades above $5,000. American Alternative Assets has released The Great Gold Reset report detailing what this gap could mean for investors.tc pixel
See More Upstream Bio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Upstream Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Upstream Bio and other key companies, straight to your email.

About Upstream Bio

Upstream Bio (NASDAQ:UPB) is a clinical-stage biotechnology company focused on the development of next-generation prophylactic vaccines and immuno-oncology therapies. Leveraging a proprietary viral vector platform, the company aims to deliver optimized antigen payloads that stimulate robust and durable immune responses against both infectious diseases and cancer targets. Upstream Bio’s approach emphasizes safety, manufacturability and potential for rapid scale-up to address emerging public health challenges.

The company’s research and development pipeline includes multiple viral vector-based candidates in early clinical and preclinical stages. In the immuno-oncology sphere, Upstream Bio is exploring therapeutic vaccine constructs designed to activate tumor-specific T cells, while its infectious disease programs seek to induce protective immunity against viral pathogens. By integrating translational biomarkers and adaptive clinical trial designs, the company strives to accelerate candidate selection and optimize dosing regimens.

Upstream Bio operates research facilities in the United States and collaborates with academic and industry partners across several regions to advance its programs globally. The company’s leadership team comprises seasoned executives and scientists with deep expertise in virology, vaccine development and regulatory affairs. Upstream Bio is listed on the Nasdaq Global Market under the symbol UPB and continues to build strategic alliances aimed at expanding its pipeline and commercial capabilities.

View Upstream Bio Profile